<DOC>
	<DOCNO>NCT02722044</DOCNO>
	<brief_summary>The purpose study evaluate usability auto-injector ( AI ) delivery M923 patient rheumatoid arthritis ( RA )</brief_summary>
	<brief_title>Usability AI M923 Subjects With Moderate Severe RA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Participants ≥18 year old time Screening 2 . Able understand communicate Investigator comply requirement study , must give write , sign date informed consent study relate activity perform . Where relevant , legal representative also sign inform study consent accord local law regulation . 3 . RA diagnose least 6 month Screening 4 . Meets classification criterion rheumatoid arthritis ( RA ) 2010 American College Rheumatology/European League Against Rheumatism criteria 5 . Active disease Screening Baseline 6 . Participants must least 1 documented swollen and/or tender joint hand wrist dominant hand assess Investigator designate assessor 7 . Must willing able attempt selfadministration subcutaneous ( SC ) injection ( ) 8 . Male participant female partner must willing comply contraception restriction study time first administration investigational product ( IP ) 3 month last dose . 9 . Female participant must negative pregnancy test screen admission clinic , must lactate must use acceptable method contraception throughout study 3 month last dose , nonchildbearing potential . Nonpregnant female partner male participant childbearing potential use effective form contraception . 1 . Prior use systemic tumor necrosis factor ( TNF ) inhibitor therapy . 2 . Prior use rituximab 3 . Prior use abatacept , tocilizumab tofacitinib within 4 week prior Screening 4 . Current use conventional disease modify antirheumatic drug ( DMARD ) following : methotrexate orally ( ≤25 mg/day ) , hydroxychloroquine ( ≤400 mg/day ) sulfasalazine ( ≤3 g/day ) ) stable dose least 4 week prior Screening . If discontinue , methotrexate , hydroxychloroquine , sulfasalazine must discontinue least 4 week prior Baseline . No conventional DMARDs permit combination therapy permit . 5 . Prior use cytotoxic alkylating agent immunosuppressant must discontinue least 90 day prior Baseline 6 . Current use oral corticosteroid dose &gt; 10 mg/day prednisone equivalent change dose within 2 week prior Screening 7 . Current use 1 nonsteroidal antiinflammatory drug . 8 . Prior use injectable corticosteroid ( intramuscular [ IM ] , intraarticular [ IA ] , intravenous [ IV ] ) within 6 week prior Baseline 9 . Prior current use selfinjected drug , eg , insulin 10 . All prior nonRA concomitant treatment must stable dose least 4 week Baseline 11 . Meets Class IV Steinbrocker criterion disability/activities daily live 12 . Laboratory abnormality Screening deem clinically significant Investigator and/or Sponsor . 13 . Presence fibromyalgia , another autoimmune rheumatologic illness inflammatory arthritis , eg , systemic lupus erythematosus , gout . The presence secondary Sjogren 's syndrome permit . 14 . Joint surgery within last 8 week prior Screening 15 . Severe , progressive , uncontrolled renal , hepatic , metabolic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac neurologic disease , include pleural effusion ascites , opinion Investigator would preclude participant adhere complete study participation study expose participant unfavorable benefit/risk 16 . History presence sign and/or symptom diagnosis demyelinate disorder 17 . History presence Class III IV New York Heart Association congestive heart failure 18 . History presence symptom suggestive lymphoproliferative disorder , lymphoma , leukemia , myeloproliferative disorder , multiple myeloma 19 . Existing malignancy history malignancy except adequately treat excised nonmetastatic basal cell squamous cell cancer skin cervical carcinoma situ , 3 lifetime basal cell squamous cell carcinomas 20 . Chronic infection , recurrent infection ( 3 infection require antiinfective treatment roll 12month period ) ; recent infection ( ie , last 30 day ) require hospitalization infection require parenteral antiinfective therapy within 30 day oral infective therapy within 14 day Baseline ; herpes zoster within 6 month Baseline 2 lifetime episode herpes zoster ; history systemic fungal infection opportunistic infection ( eg , coccidioidomycosis , histoplasmosis , toxoplasmosis ) 21 . History presence human immunodeficiency virus ( HIV ) , Hepatitis B C virus 22 . History active tuberculosis ( TB ) untreated inadequately treat latent TB . 23 . Participant expose investigational product ( IP ) within 30 day ( 5 halflives ) prior enrollment , whichever longer , schedule participate another clinical study involve IP investigational device course study 24 . Participant family member employee Investigator Baxalta partner</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>